SETTING: Two large cities in the Philippines. OBJECTIVES: To describe the problems of drug-resistant tuberculosis (TB) in an urban setting, with special emphasis on their potential impact on the treatment services provided by the National TB Control Programme. DESIGN: Cross-sectional survey and cohort analysis of treatment outcomes. METHODS: All patients with positive sputum smear examination results in Cebu and Mandaue cities during the survey period were included. The survey procedures of the World Health Organization and the International Union Against Tuberculosis and Lung Disease were strictly applied. Treatment outcome data were also collected. RESULTS: Of 306 cases enrolled, 255 were new cases, 28 were previously treated and for 23 treatment history was unknown. Of the new cases, 72.2% were pan-susceptible to all four first-line anti-tuberculosis drugs. Resistance in new cases was 16.9% to isoniazid (INH), 4.7% to rifampicin (RMP), 3.1% to ethambutol, 18.0% to streptomycin, and 3.9% to at least both INH and RMP (multidrug-resistant [MDR]). Over 90% of the new cases, either pan-susceptible or mono-resistant, were successfully treated with the standard regimen, but four of nine MDR new cases could not be cured. CONCLUSION: The drug resistance level was high in this population, but treatment outcome using the standard treatment regimen was not seriously affected unless the patients were MDR.
SETTING: Two large cities in the Philippines. OBJECTIVES: To describe the problems of drug-resistant tuberculosis (TB) in an urban setting, with special emphasis on their potential impact on the treatment services provided by the National TB Control Programme. DESIGN: Cross-sectional survey and cohort analysis of treatment outcomes. METHODS: All patients with positive sputum smear examination results in Cebu and Mandaue cities during the survey period were included. The survey procedures of the World Health Organization and the International Union Against Tuberculosis and Lung Disease were strictly applied. Treatment outcome data were also collected. RESULTS: Of 306 cases enrolled, 255 were new cases, 28 were previously treated and for 23 treatment history was unknown. Of the new cases, 72.2% were pan-susceptible to all four first-line anti-tuberculosis drugs. Resistance in new cases was 16.9% to isoniazid (INH), 4.7% to rifampicin (RMP), 3.1% to ethambutol, 18.0% to streptomycin, and 3.9% to at least both INH and RMP (multidrug-resistant [MDR]). Over 90% of the new cases, either pan-susceptible or mono-resistant, were successfully treated with the standard regimen, but four of nine MDR new cases could not be cured. CONCLUSION: The drug resistance level was high in this population, but treatment outcome using the standard treatment regimen was not seriously affected unless the patients were MDR.
Authors: Guang Xue He; Yan Guang Xie; Li Xia Wang; Martien W Borgdorff; Marieke J van der Werf; Ji Huan Fan; Xing Lu Yan; Fa Bin Li; Xue Zhi Zhang; Yan Lin Zhao; Susan van den Hof Journal: PLoS One Date: 2010-05-24 Impact factor: 3.240
Authors: Federica Fregonese; Shama D Ahuja; Onno W Akkerman; Denise Arakaki-Sanchez; Irene Ayakaka; Parvaneh Baghaei; Didi Bang; Mayara Bastos; Andrea Benedetti; Maryline Bonnet; Adithya Cattamanchi; Peter Cegielski; Jung-Yien Chien; Helen Cox; Martin Dedicoat; Connie Erkens; Patricio Escalante; Dennis Falzon; Anthony J Garcia-Prats; Medea Gegia; Stephen H Gillespie; Judith R Glynn; Stefan Goldberg; David Griffith; Karen R Jacobson; James C Johnston; Edward C Jones-López; Awal Khan; Won-Jung Koh; Afranio Kritski; Zhi Yi Lan; Jae Ho Lee; Pei Zhi Li; Ethel L Maciel; Rafael Mello Galliez; Corinne S C Merle; Melinda Munang; Gopalan Narendran; Viet Nhung Nguyen; Andrew Nunn; Akihiro Ohkado; Jong Sun Park; Patrick P J Phillips; Chinnaiyan Ponnuraja; Randall Reves; Kamila Romanowski; Kwonjune Seung; H Simon Schaaf; Alena Skrahina; Dick van Soolingen; Payam Tabarsi; Anete Trajman; Lisa Trieu; Velayutham V Banurekha; Piret Viiklepp; Jann-Yuan Wang; Takashi Yoshiyama; Dick Menzies Journal: Lancet Respir Med Date: 2018-04 Impact factor: 102.642